CompletedNCT02051387
Cannabidiol Delivery and Drug Interactions in Schizophrenia
About this title
Read the official source — NCT02051387Medication studyAges 18–45Germany
Understand this study
Who was this study for?
Listed age limits: 18 years to 45 years.
- Listed locations
- Mannheim and 1 more locationSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateJanuary 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 74
- Sponsor
- Central Institute of Mental Health, Mannheim
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Germany
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT02051387
- Official title
Show the full official title
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study With Approved Antipsychotics in Vivo
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Mannheim · Cologne
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Central Institute of Mental Health, Mannheim, a research institute.
Did this study involve medication?
Yes. The study involved medication, including Cannabidiol CR, Cannabidiol, Amisulpride, Olanzapine, Quetiapine, Risperidone and Placebo.
Who was this study for?
Listed age limits: 18 years to 45 years.
Want to explore more studies?
Explore studiesRelated studies
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
Long-Term Safety of EVP-6124 Added to Schizophrenia Medication